From QSAR to Big Data: Developing Mechanism-Driven Predictive Models for Animal Toxicity

Similar documents
Chemical safety and big data: the industry s demands

In Silico Models: Risk Assessment With Non-Testing Methods in OSIRIS Opportunities and Limitations

dixa a data infrastructure for chemical safety Jos Kleinjans Dept of Toxicogenomics Maastricht University

How to create and interpret the predictive analysis of a compound

Biological importance of metabolites. Safety and efficacy aspects

Guidance for Industry Safety Testing of Drug Metabolites

Derek Nexus and Sarah Nexus: working together for ICH M7

Edward Odenkirchen, Ph.D. Office of Pesticide Programs US Environmental Protection Agency

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective

M The Nucleus M The Cytoskeleton M Cell Structure and Dynamics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Guidance for Industry

Big Data in Drug Discovery

QSAR. The following lecture has drawn many examples from the online lectures by H. Kubinyi

Data Visualization in Cheminformatics. Simon Xi Computational Sciences CoE Pfizer Cambridge

Enzyme Response Profiling: Integrating proteomics and genomics with xenobiotic metabolism and cytotoxicity

Mitigation Strategies for Reactive Intermediates in

Introduction. MassDEP, Office of Research and Standards 1 Tetrachloroethylene

Dr Alexander Henzing

Cheminformatics and its Role in the Modern Drug Discovery Process

Academic Drug Discovery in the Center for Integrative Chemical Biology and Drug Discovery

PRACTICAL APPROACH TO ECOTOXICOGENOMICS

NAFTA TWG Sound Science and Policy

High-Throughput Screening at The University of Chicago Cellular Screening Center. Sam Bettis Technical Director

BIOMARKERS AND TOXICITY MECHANISMS 06 Mechanisms Metabolism & Detoxification. Luděk Bláha, PřF MU, RECETOX

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN

Non-clinical development of biologics

Risk Assessment in Chemical Food Safety. Dept. of Food Safety and Zoonoses (FOS)

Basic Overview of Preclinical Toxicology Animal Models

DMPK: Experimentation & Data

Guidance for Industry

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule

The Scheduled MRM Algorithm Enables Intelligent Use of Retention Time During Multiple Reaction Monitoring

Apply with Resume to: Submenu Path Company/Careers/Current Openings/Job Type: Science

Your partner in immunology

Call 2014: High throughput screening of therapeutic molecules and rare diseases

The Global Biotech Company

Molecular descriptors and chemometrics: a powerful combined tool for pharmaceutical, toxicological and environmental problems.

Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation

Lecture 11 Data storage and LIMS solutions. Stéphane LE CROM

Supporting Information

Integrating Medicinal Chemistry and Computational Chemistry: The Molecular Forecaster Approach

The Clinical Trials Process an educated patient s guide

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Chemical Risk Assessment in Absence of Adequate Toxicological Data

Running Large Workflows in the Cloud

Copyright Soleran, Inc. esalestrack On-Demand CRM. Trademarks and all rights reserved. esalestrack is a Soleran product Privacy Statement

Elastomeric Components for Pharmaceutical Applications - Actual Quality Trends - Claudia Petersen. -Senior Manager Biotechnology-

Analyzing microrna Data and Integrating mirna with Gene Expression Data in Partek Genomics Suite 6.6

The Physiology of Hyperbaric Oxygen Therapy. Free Radicals and Reactive Oxygen Species. I. Introduction Definition, Source, function and Purpose

Combinatorial Chemistry and solid phase synthesis seminar and laboratory course

Treatment and Management of Oil Sands Tailings Water for Detoxification and Decontamination

ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

Antioxidant Products. A comprehensive range of. Antioxidants

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

Essentials of Real Time PCR. About Sequence Detection Chemistries

岑 祥 股 份 有 限 公 司 技 術 專 員 費 軫 尹

Lead optimization services

STRUCTURE-GUIDED, FRAGMENT-BASED LEAD GENERATION FOR ONCOLOGY TARGETS

Rapid Pharma Development GmbH. Impurities in the contexts of CMC Development

Fighting the Battles: Conducting a Clinical Assay

Guidance on information requirements and chemical safety assessment. Chapter R.2: Framework for generation of information on intrinsic properties

Biology Institute: 7 PhD programs Expertise in all areas of biological sciences

Analytical Chemistry Lab Reports

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD

Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents

Product Datasheet. Secreted Alkaline Phosphatase Reporter Kit NBP Unit Size: 1 Kit. Storage is content dependent.

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials

8 9 +

Kinexus has an in-house inventory of lysates prepared from 16 human cancer cell lines that have been selected to represent a diversity of tissues,

Digital Pathology Image Analysis with Definiens

Crossing the drug development divide

We use Reaxys intensively for hit identification, hit-to-lead and lead optimization.

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

Putting ecological realism in environmental risk assessment

Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation

Transcription:

From QSAR to Big Data: Developing Mechanism-Driven Predictive Models for Animal Toxicity Hao Zhu Department of Chemistry The Rutgers Center for Computational and Integrative Biology Rutgers University-Camden Email: hao.zhu99@rutgers.edu September 24, 2015 1

Acknowledgements Rutgers: PhD students: Marlene Kim, Wenyi Wang, Daniel Russo, Linlin Zhao Master students: Kathryn Ribay, Joe Hess Visiting Scholar: Dr. Aleck Sedykh, Dr. Jun Zhang John Hopkins University: Dr. Thomas Hartung Shandong University: Dr. Bing Yan CATS: Dr. Menghang Xia, Dr. Ruili Huang ICCVAM: Dr. Judy Strickland Funding resource: ational Institute of Health: 1R15ES023148 Society of Toxicology: Colgate-Palmolive Grant for Alternative Research 2

Toxicity evaluation today Collins, F. S., Gray, G. M. and Bucher J. R. Science, 2008, 319, 906-907 3

Principles of QSAR modeling 0.613 D E S C R I P T R S Quantitative Structure Activity Relationships Slide Courtesy of Dr. Fourches 0.380-0.22 1.450 0.708 1.146 0.491-0.30 0.141 0.956 0.256 0.799 P R P E R T Y 4

Principles of QSAR modeling D E S C R I P T R S 0.613 0.380-0.22 1.450 0.708 1.146 0.491-0.30 0.141 0.956 0.256 0.799 P R P E R T Y

The similar compounds that have dissimilar toxicity profiles ACEA_IC50 TES: I VITR ASSAYS 0: non-toxic/inactive 1: toxic/active -: not tested : earest eighbor ATG_AHR_CIS CELLLSS_24HR P53ACT_24HR VS_ADME_RCYP3A2 VS_MP_HPBR SLIDUS_P450 I VIV ASSAYS MUSE_KIDEY RAT_SKELETAL_AXIAL MGR_RAT_LIVER MGR_RAT_KIDEY 0 0 0 0 1 1 0 0 0 0 0 METLACHLR Cl 1 0 1 1 0 1 1 1 1 1 1 Cl 1-ACETCHLR 1 0 1 1 0 1 1-0 - - 2-ALACHLR Cl 0 1 0 0 0 0 0 0 1 1 0 3-METALAXYL 6

PubChem data in 2014 >700,000 bioassays >200,000,000 bioactivity outcomes >1,200,000,000 data points >2,800,000 small molecule samples >1,900,000 chemical structures >108,000 RAi reagents Yang et al. ucleic Acids Res. 2014 Jan;42: D1075-82 7

Chemical-in vitro-in vivo profiles in big data era Chem. Res. Tox. 2014; (27) 1643-1651 8

Before the ToxCast project, data already existed btained from PubChem on Aug. 1, 2013, before the ToxCast phase II data was released. 9

The current question is: What can we do if we have limited in-house data available for the compounds of interest? 10

Antioxidant Response Element β-lactamase reporter gene assay (ARE-bla) Recognized by the Tox21 program as one of the most important toxicity assays ARE genes play a role in alleviating oxidative stress Shukla SJ, et al. Environ Health Perspect. 2012, 120(8):1150-6.

Reactive xygen Species (RS)? Liver damage

Workflow for profiling liver toxicants

Profiling target compounds with biological responses using automated tool Input target compounds: 1. qhts ARE-bla dataset (10,928 compounds) 2. FDA liver damage dataset (1,314 compounds) utput assays related to: 1. qhts ARE-bla activation (1,819 assays) 2. Liver damage (1,159 assays)

Criteria for filtering inadequate and finding relevant assays 2,978 Initial number of assays retrieved 958 Must appear in both groups (qhts ARE-bla and liver damage) 20 Contained >10 true positive responses Correlation was better than random (CCR >50%) 14 In vitro assay 4 Evidence supported by reliable literature

Individual assays showed poor IIC, but the combined response using RA>0.25 show statistical significance Bioassay p-value Compounds Liver damage activity -- 686978 0.59 743067 0.42 743140 0.24 (ARE-bla) 743202 0.31 Combined 4.25x1 0-4 TP and F T F FP and T Active or toxic Inconclusive or untested Inactive or non-toxic Rate of actives (RA) RRRR = AA AA + II A = no. of active responses I = no. in active responses

Modeling qhts ARE-bla activation using QSAR approaches: 5-fold cross validation for all individual models 0.80 Sensitivity Specificity CCR 0.70 Rate 0.60 0.50 RF_ME SVM_ME k_me RF_Drg SVM_Drg k_drg Consensus QSAR Models

Evaluating In vitro-in vivo Correlations (IICs) Focused on compounds that were active in qhts ARE-bla and liver toxic Searched for common chemical features Evaluated IICs (sensitivity, specificity, CCR, and Χ 2 )

IIC between qhts ARE-bla activation and liver damage for overlapping compounds containing the toxicophores A) TP T FP F B) TP T FP F 120 H 120 H 100 H H 100 H 80 80 60 60 40 40 20 20 0 ARE-bla ARE-bla + QSAR CCR = 0.64 CCR = 0.60 0 ARE-bla ARE-bla + QSAR CCR = 0.61 CCR = 0.57

3-D plot of Tox21 phase II modeling set vs FDA liver damage dataset using principal components analysis

Liver toxicity mechanism analysis involving ARE pathway perturbations

Conclusions Developed a workflow Profiles biological responses from big data Incorporates QSAR models to fill-in missing data Evaluates the chemical IIC Identified toxicophores and assays that can be used to assess liver damage induced by oxidative stress Workflow can be adapted to model or assess other complex animal toxicity endpoints Mechanism profiling liver toxicants by using antioxidant response element assay data model and public big data. Environ. Health Perspect. In press

Take home message Reliable information exists, but it is difficult to locate Good data may not guarantee good decisions 23